Veracyte
Veracyte is a genomic diagnostics company focused on resolving diagnostic uncertainty and guiding care in selected disease areas. Its platform includes genomic classifiers and molecular tests used in fields such as thyroid cancer, prostate cancer, breast cancer, lung cancer, and interstitial lung disease.
- Genetic Testing & Genomics Providers
Overview
Veracyte is a genomic diagnostics company focused on resolving diagnostic uncertainty and guiding care in selected disease areas. Its platform includes genomic classifiers and molecular tests used in fields such as thyroid cancer, prostate cancer, breast cancer, lung cancer, and interstitial lung disease.
The company’s importance lies in clinical decision support. Some genetic and genomic tests are not broad sequencing panels but disease-specific classifiers designed to clarify whether surgery, biopsy, surveillance, or treatment is appropriate. This type of genomic diagnostic can influence care pathways even when it is narrower than comprehensive genomic profiling.
Veracyte is included in 2 2026 ranking categories. Its highest classification is Tier II. Ranking recognition is category-specific editorial evidence rather than a substitute for independent diligence.
Firm facts
| Public identity | Veracyte |
| Formation history | 2006 — incorporated as Calderome; renamed Veracyte in 2008 |
| Institution type | Genetic Testing & Genomics Providers institution |
| Headquarters | South San Francisco, United States |
| Primary focus | Genetic Testing & Genomics Providers |
Contents
- Principal activities
- Sector and mandate coverage
- Market position
- Competitive context
- Leadership and governance
- Corporate and public information
- Additional published ranking appearances
- Company structure and assessed businesses
- Rankings and recognition
- Related Economy analysis
- Related institutions and subjects
- Sources and data transparency
Principal activities
The company’s importance lies in clinical decision support. Some genetic and genomic tests are not broad sequencing panels but disease-specific classifiers designed to clarify whether surgery, biopsy, surveillance, or treatment is appropriate. This type of genomic diagnostic can influence care pathways even when it is narrower than comprehensive genomic profiling.
Core capability
Genetic Testing & Genomics Providers
Client relevance
Category-specific capability, institutional credibility and the ability to support demanding professional, commercial or patient needs.
Execution and verification
Current service scope, leadership, geographic coverage, legal entities and regulated activities should be confirmed directly.
Sector and mandate coverage
Primary category
Genetic Testing & Genomics Providers
Institutional context
Coverage reflects the institution’s role in the ranking categories listed below. Precise services, products, jurisdictions, clinical scope and client eligibility should be verified for each use case.
Market position
Veracyte’s focused test portfolio, clinical utility orientation, and role in specialty decision-making support its inclusion among established genetic testing and genomics providers.
Veracyte is assessed through public institutional information and Ranking News editorial research. Its strongest 2026 result is Tier II.
Competitive context
The relevant peer set varies by category, geography, client segment and mandate. Veracyte should be compared on current category-specific capability, senior involvement, evidence of comparable work, operating resilience and any applicable regulatory or clinical permissions.
Comparable institutions are shown for navigation and market context. Inclusion does not imply identical scale, ownership, geographic coverage, service model or regulatory status.
Leadership and governance
Leadership, ownership, governance and senior-team responsibilities may change. Current information should be verified through authoritative institutional sources.
Corporate and public information
The public-facing organization is identified here as Veracyte. Contracting entities, regulated affiliates, clinical operations, offices and legal permissions may differ by service and jurisdiction.
Corporate and disclosure information
| Organization | Veracyte |
| Headquarters | South San Francisco, United States |
| Verification note | Confirm legal entity, licenses, offices and engagement terms directly before appointment or use. |
Additional published ranking appearances
These entries retain the edition, classification and assessed business name published in the source. Historical entries describe that edition, including businesses whose ownership or name later changed.
| Published ranking | Edition / tier | Assessed business |
|---|---|---|
| Top 20 Precision Medicine Diagnostics Providers 2025 | 2025 · Tier II | Veracyte |
| Top 20 Genetic Testing & Genomics Providers 2025 | 2025 · Tier II | Veracyte |
| Top 20 Precision Medicine Diagnostics Providers 2024 | 2024 · Tier II | Veracyte |
| Top 20 Genetic Testing & Genomics Providers 2024 | 2024 · Tier II | Veracyte |
| Top 20 Precision Medicine Diagnostics Providers 2023 | 2023 · Tier II | Veracyte |
| Top 20 Genetic Testing & Genomics Providers 2023 | 2023 · Tier II | Veracyte |
Company structure and assessed businesses
Veracyte is a molecular cancer-diagnostics company headquartered in South San Francisco, California. Veracyte and Veracyte Inc refer to the same business; diagnostic-product assessments and employer assessments retain their separate scope.
Primary sources: company reference 1.
Assessed business: Veracyte Inc
Veracyte Inc is profiled in The Economy Rankings across Employers for Research & Innovation Careers, Pharmaceutical & Biotechnology Employers, Employers for Organizational Trust.
Business-specific facts retained from the earlier Veracyte Inc assessment; dates and locations refer to that business scope.
| Assessed U.S. headquarters / base | San Diego, CA, US |
| Reported business origins | 2008 |
The category profiles below describe the named businesses, products, programmes or employee groups assessed in the linked rankings. Their scope follows each source.
Top 30 Employers for Organizational Trust 2027 — Veracyte Inc
Veracyte combines biological assay development and genomic diagnostics with laboratory, research and bioinformatics work. Its workforce filing describes employee-led communities supporting professional development, connection and engagement. This establishes an employment mechanism alongside the technical roles, while biological testing and assay research place the employer within the biotechnology scope rather than treating it as a general software vendor.
Great Place To Work’s U.S. profile, updated November 2025, reports 90% overall workplace endorsement. A published employee item records 93% agreement: “Management is honest and ethical in its business practices.”
- Employing entity / assessed group: Veracyte Inc (assessed U.S. employing group)
- Assessed workforce: U.S. directly employed workforce in provider cohort; contractors and unassessed foreign affiliates excluded.
- Assessed U.S. headquarters / base: San Diego, CA, US
- Reported business origins: 2008
Top 30 Employers for Research & Innovation Careers 2027 — Veracyte Inc
Veracyte’s scientific employment spans biological assay research, laboratory work and bioinformatics. Its workforce filing describes employee-led communities supporting professional development, connection and engagement. This links identifiable scientific disciplines with an operating employee mechanism, rather than treating genomic technology or diagnostic accuracy alone as evidence of an attractive research career.
The combination is relevant to work that draws on both biological and analytical expertise. The filing and careers record establish actual professional roles and development support, while the US employee evidence supplies wider organizational context. It does not establish identical experiences across research, commercial and office functions, or show that every community participant progresses to a more senior role.
- Assessed workforce: US employees in documented scientific/research-development work and professional support; role and programme eligibility applies.
Top 30 Pharmaceutical & Biotechnology Employers 2027 — Veracyte Inc
Veracyte combines biological assay development and genomic diagnostics with laboratory, research and bioinformatics work. Its workforce filing describes employee-led communities supporting professional development, connection and engagement. This establishes an employment mechanism alongside the technical roles, while biological testing and assay research place the employer within the biotechnology scope rather than treating it as a general software vendor.
Great Place To Work’s U.S. profile, updated November 2025, reports 90% overall workplace endorsement. A published employee item records 93% agreement: “Management is honest and ethical in its business practices.”
| Ranking | Edition / classification | Assessed scope |
|---|---|---|
| Employers for Research & Innovation Careers | 2027 · Tier I · position 5 | US employees in documented scientific/research-development work and professional support; role and programme eligibility applies. |
| Pharmaceutical & Biotechnology Employers | 2027 · Tier III | U.S. directly employed workforce in provider cohort; contractors and unassessed foreign affiliates excluded. |
| Employers for Organizational Trust | 2027 · Tier II | U.S. directly employed workforce in provider cohort; contractors and unassessed foreign affiliates excluded. |
Rankings and recognition
Ranking inclusion and tier classification are editorial determinations. They should be read as category-specific assessments rather than universal league-table positions. The existence or maintenance of this Wiki profile does not influence ranking eligibility, tier or position.
Related Economy analysis
Selected reporting and market analysis from The Economy provides context for the institution’s operating environment:
- Healthcare Rankings and the New Economics of Expertise
- Healthcare Market Structure Is Opening a New Lane for Specialist Providers
- Healthcare Rankings and the New Geography of Distributed Care
Related institutions and subjects
Sources and data transparency
Official institutional information, where available, is used for current public identity and capabilities. Ranking pages document 2026 category and tier status. Economy articles provide market context rather than institution-specific endorsement.
- Healthcare Ranking — Top 30 Genetic Testing & Genomics Providers 2026 — 2026 inclusion and tier classification.
- Healthcare Ranking — Top 30 Precision Medicine Diagnostics Providers 2026 — 2026 inclusion and tier classification.
- The Economy — Healthcare Rankings and the New Economics of Expertise — market context.
- The Economy — Healthcare Market Structure Is Opening a New Lane for Specialist Providers — market context.
- The Economy — Healthcare Rankings and the New Geography of Distributed Care — market context.
Corrections and Updates
Factual corrections, updated institutional information, and supporting references may be submitted through The Economy Portal. All proposed changes are subject to editorial verification before publication.